rstupp

Department of Clinical Neurosciences and University of Lausanne, Lausanne, Switzerland. Roger Stupp, M.D. is head of the Department of Oncology-Hematology of the Riveria/Chablais region at the hospitals of Vevey and Monthey, Switzerland, and he serves as Attending Physician at the Department of Neurosurgery of University of Lausanne Medical Center (CHUV) where he leads the multidisciplinary brain tumor clinic. Dr. Stupp is an active and dedicated clinical researcher. His special clinical interests include the multimodality management of brain tumors, head and neck and lung cancers, new drug development and the association of chemotherapy and radiation therapy. He is closely involved in bringing new antiangiogenic and biological treatments to the clinic. Roger Stupp has been the lead investigator for establishing temozolomide chemotherapy in conjunction with radiotherapy in newly diagnosed glioblastoma, and determining the predictive value of MGMT gene promoter methylation. Recent work includes the association of the integrin inhibitor cilengitide in addition to chemoradiotherapy, currently under investigation in a randomized phase III trial and development and conduct of the recently reported RTOG0525-EORTC-NCCTG Intergroup phase III trial aiming at overcoming temozolomide resistance. Together with his colleagues from the Swiss Group of Clinical Cancer Research (SAKK) he reported on curative tri-modality therapy including neoadjuvant chemo- and radiotherapy before definitive surgery in stage III B non-small cell lung cancer. The value of the addition of preoperative radiotherapy is under investigation in a randomized phase III trial in patients with stage IIIA/N2 disease. He serves as Vice President for European Organization for Research and Treatment of Cancer (EORTC) and Member of the Executive Committee, and is the past Secretary of the EORTC Brain Tumor Group. Dr. Stupp is an editor for the European Journal of Cancer, and is a member of several editorial boards including Journal of Clinical Oncology, and Neuro-Oncology.